|Other Names||Serine/threonine-protein kinase B-raf, Proto-oncogene B-Raf, p94, v-Raf murine sarcoma viral oncogene homolog B1, BRAF, BRAF1, RAFB1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP3513a was selected from the region of human Phospho-BRAF-pT400. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction pathway.|
|Cellular Location||Nucleus. Cytoplasm. Cell membrane. Note=Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes.|
|Tissue Location||Brain and testis.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
BRAF is involved in the transduction of mitogenic signals from the cell membrane to the nucleus. It may play a role in the postsynaptic responses of hippocampal neurons. Defects in BRAF are a cause of cardiofaciocutaneous syndrome (CFC syndrome), and a wide range of cancers such as lung cancer, non-Hodgkins lymphoma, and colorectal cancer.
Loewe, R., et al., J. Invest. Dermatol. 123(4):733-736 (2004).Yamaguchi, T., et al., J. Biol. Chem. 279(39):40419-40430 (2004).Frattini, M., et al., Oncogene 23(44):7436-7440 (2004).Tsavachidou, D., et al., Cancer Res. 64(16):5556-5559 (2004).Gear, H., et al., Invest. Ophthalmol. Vis. Sci. 45(8):2484-2488 (2004).
If you have any additional inquiries please email technical services at email@example.com.